InsidersTradesSigma
지에프씨생명과학 Stock: price and directors' dealings · South Korea · DART (FSS)
Track the 지에프씨생명과학 stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are quoted on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 지에프씨생명과학 has published 6 reports. Market capitalisation: €29.8bn. The latest transaction was reported on 10 April 2026 (Purchase). Among the most active insiders: 강희철. The full history is free.
6
Insider Decl.
n/a
Thresholds
€210,842
6 ops.
Buy Volume
n/a
n/a
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,831 of 28,169 companies
35.5
score / 100
Value26
Quality45
FCF yld-20%
Earn yld1.8%
EV/EBITDA18.5x
ROE4.1%
Gross mgn48%
Net mgn3.1%
Debt/EBITDA3.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 10 April 2026
Declarations6 total
6 of 6 declarations
About 지에프씨생명과학
지에프씨생명과학 is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for healthcare.